Safety and Efficacy of suvorexant (MK-4305) for the treatment of insomnia in AD subjects

Update Il y a 4 ans
Reference: EUCTR2015-003154-40

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

(1) To evaluate the efficacy of suvorexant compared with placebo in improving insomnia, as measured by change from baseline in PSG-derived total sleep time (TST), at Week 4. (2) To evaluate the safety and tolerability of suvorexant for up to 4 weeks of treatment.


Inclusion criteria

  • Insomnia

Links